NextBio sees demand for translational research service

Santa Clara, CA-based NextBio tells Xconomy that an increasing number of physicians are coming to the company for assistance with interpreting genomic reports to help inform treatment decisions for their patients. As the price of genetic sequencing continues to drop, there's a growing need for services that translate masses of data into usable knowledge. NextBio says physicians are using their service to make last-ditch attempts at understanding a patients' disease on a genetic level in order to explore alternative treatment options. Article

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.